| |SEPTEMBER 20248SUN PHARMA LAUNCHES NOVEL TREATMENT IN INDIAALKEM LABORATORIES SECURES ACCESS TO EXATECH'S TECHNOLOGY VIA PARTNERSHIPSun Pharmaceutical Industries Limited introduced tedizolid phosphate tablets 200 mg in India with the brand name "Starizo". Starizo (tedizolid phosphate) is a new antibiotic in the oxazolidinone class, prescribed for acute bacterial skin and skin structure infections (ABSSSI). Sun Pharma has been granted permission by MSD to produce, develop, and sell tedizolid phosphate in India."Drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) causing ABSSSIs, are more challenging to treat due to the limited availability of effective treatment options in hospitals. With Starizo, we are introducing a treatment option which is effective and has the convenience of once-a-day dosing", said Kirti Ganorkar, CEO - India business, Sun Pharma. "At Sun Pharma, it has always been our endeavour to introduce innovative medicines that help improve the quality of life of patients," he added. Skin and soft tissue infections made up approximately 29-32 percent of all infections in India in 2018-2019, being the most prevalent type of infections. The prevalence of MRSA in India has risen annually, going up from 28.4 percent in 2016 to 42.6 percent in 2021 (S. aureus infections). Bacteria that are resistant to drugs, like MRSA which leads to ABSSSIs, are harder to treat because there are few effective antibiotics available. POAlkem Laboratories has become the first Indian pharmaceutical company to venture into medical devices, following a partnership with US-based Exactech to produce and market its joint replacement implants in India. Through this agreement, Exactech, headquartered in Gainesville, Florida, will grant Alkem MedTech, a subsidiary of Alkem Laboratories, access to the designs, technology, and marketing rights of its well-known knee and hip implant brands such as Truliant, Optetrak, Logic Fit, Alteon, AcuMatch, Novation, and Novation CFS. Alkem will manufacture and distribute these implants in the Indian market.Although Alkem has not provided specifics about investments or whether it will establish a new manufacturing facility or opt for contract manufacturing, the partnership is considered a significant advancement in Indian medical device manufacturing. Kaustav Banerjee, CEO of Alkem MedTech, stated that the agreement aligns with India's mission to promote the domestic production of high-precision medical devices.India's orthopedic implant market, valued at 4,838 crores in 2023, is anticipated to grow at a compound annual growth rate (CAGR) of 9.23 percent by 2030. The market is dominated by knee-replacement products, followed by trauma and spine segments. POTOP STORIES
< Page 7 | Page 9 >